Document is current
Any future updates will be listed below
-
Authors
Kleinfelder, Karina http://orcid.org/0000-0003-1267-4814
Melotti, Paola
Hristodor, Anca Manuela
Fevola, Cristina
Taccetti, Giovanni
Terlizzi, Vito
Sorio, Claudio http://orcid.org/0000-0003-2739-4014
-
Funding
Funding for this research was provided by:
Fondazione per la Ricerca sulla Fibrosi Cistica (#13/2018, #9/2020)
Cystic Fibrosis Foundation (Assael08A0)
Ministero dell’Istruzione, dell’Università e della Ricerca (2022FRSS2H)
- License Information
-
More Information
Article History
Received: 25 January 2024
Accepted: 21 August 2024
First Online: 13 September 2024
Declarations
:
: The study was approved by the Ethical committee of the CF center of Florence (Ethics Commit-tee Numbers 194/2019 and 110/2021) and CF center of Verona (Ethics Committee number CRCFC-CFTR050). Informed consent was obtained from all patients (or from their legal guardians) for the use of anonymous clinical data for research purposes.
: Informed consent was obtained from all patients (or from their legal guardians) for the use of anonymous clinical data for research purposes.
: PM acted as paid expert testimony for Vertex Pharmaceuticals and declares no conflict of interest. The other authors declare no conflict of interest.
